Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
about
Chemotherapy for advanced non-small cell lung cancer in the elderly populationSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseChemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancerSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsIs there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel.First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II studyBortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.[A randomized clinical trial on the clinical efficacy and toxicities of single-agent paclitaxel liposome versus paclitaxel liposome plus oxaliplatin as first-line chemotherapy for advanced non-small cell lung cancer in elderly patients].[A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer].Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002).Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer.Differences in clinical trial patient attributes and outcomes according to enrollment setting.Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma.Effect of pazopanib on tumor microenvironment and liposome deliveryMeasuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participantsSensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.Treating advanced non-small cell lung cancer in the elderly.The association of transporter genes polymorphisms and lung cancer chemotherapy responseCustomizing systemic therapy in patients with advanced non-small cell lung cancer.Management of elderly patients.TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment.Therapeutic options in older patients with metastatic non-small cell lung cancer.Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.EGFR inhibitors: what have we learned from the treatment of lung cancer?Second- and third-line treatments in non-small cell lung cancer.First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
P2860
Q24186466-B522FD3E-07E1-4C85-87AB-77F3026C17CAQ24200518-00466C53-8A25-4FB8-A60A-2822719141BAQ24235422-4FA95E0C-84D2-4473-93A4-7940368D2478Q24243664-A7EEEF6D-5D9F-4BD7-A051-1D55E35ED199Q24643017-0EF9F038-B6C1-4C06-AD52-E823FBD8AEFFQ26766180-EA19C31A-BEA0-453A-86BB-B33E55E22AD0Q26798674-4AF5B6EF-9647-4E76-B316-0036BF7FE9ACQ28081243-0EAEA084-9A8C-40DA-8435-C2F0905F50ACQ30438068-3C83D9AB-674A-4A66-A5D7-271EF255D07DQ30670518-01713B09-A881-403B-8BA3-0861D4155CCEQ30890572-A56D3C6A-44B2-435F-8119-3BA73D396881Q33366782-C1A41E52-C17B-461F-9B53-DE6F1AE452B4Q33374962-6811C737-AAD8-47EC-B174-50EC5E1315CBQ33378383-4F9596A0-D5EA-4E66-8CCF-05636CB16AF1Q33382525-FF92D6E8-FA6B-4A62-9AA4-E14B9391468DQ33396073-E6D98599-F4F1-4880-A4F3-A21DE2B08226Q33399713-F0484AD2-84C6-4786-B604-9C5AFA8DF7D4Q33401712-8A2DBDF1-C19A-4AB4-990D-7C6225AAEA56Q33411167-E296CD5D-D1FA-4625-BF6D-5C3F6B540744Q33421926-EB374A1C-6475-420E-B67B-FEB218905F91Q33422429-68D689C0-B760-4AE8-BB69-B95A6F5F2F74Q33429178-79E1A832-DB1E-4ED6-8903-EDCA95C8EBD4Q33627769-C3BB47C0-BF7B-4DFD-B0CF-9F8D80B0D291Q33685172-207DE008-4031-4129-8E0D-C57EECF4AEDFQ34018204-EA162AF0-564D-428B-90B9-B330F29EF8D7Q34150896-C897E4DC-311C-428B-BAB4-43C591E2A697Q34192086-B0440B8C-0EC5-4E94-B796-BAD32265E859Q34433040-58EFFB67-4534-4906-B40E-A783F412F616Q34736580-E8ABA541-9E72-4990-A8B4-508030370D4BQ34786733-2B094A85-18B8-4F3F-AF69-431291B075D2Q35076283-1B72C353-1E3B-4502-AB63-640B3C6B38D4Q35124361-C05EA322-226A-4C18-9E65-7D3E46E4CE6AQ35146940-F8DAE0C8-F258-46C1-9E2D-4ECB49706594Q35200398-3FA6EE3A-3123-405F-9410-D745E36E99E3Q35646576-44606664-41E1-48FD-BBDA-63BEDA94DC1CQ36180083-0BCF119A-7D36-4A49-A490-79E3F89E61C9Q36299985-984AC35A-839E-404C-8A86-8AEB3CA140C5Q36306259-CF047464-EEBC-4765-9005-C8058987C1D2Q36338853-D46565CD-4469-468E-BECA-51C6DCF5F9F3Q36368641-B83DEAFC-FB86-4F07-B062-34F3557A1E8E
P2860
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Single-agent versus combinatio ...... leukemia group B (study 9730).
@en
Single-agent versus combinatio ...... he cancer and leukemia group B
@nl
type
label
Single-agent versus combinatio ...... leukemia group B (study 9730).
@en
Single-agent versus combinatio ...... he cancer and leukemia group B
@nl
prefLabel
Single-agent versus combinatio ...... leukemia group B (study 9730).
@en
Single-agent versus combinatio ...... he cancer and leukemia group B
@nl
P2093
P356
P1476
Single-agent versus combinatio ...... leukemia group B (study 9730).
@en
P2093
Antonius A Miller
Chris Desch
Dorothy M Watson
James E Herndon
Jane C Weeks
Marcy A List
Mark R Green
Michael C Perry
Philippe Chahinian
Rogerio C Lilenbaum
P304
P356
10.1200/JCO.2005.07.172
P407
P577
2005-01-01T00:00:00Z